Affordable Access

Thrombolytic Treatment After Acute Ischemic Stroke Results from the Minnesota Stroke Registry and Opportunities to Improve Care.

Authors
  • Lakshminarayan, Kamakshi1
  • Peacock, James M
  • Luepker, Russell V
  • Tsai, Albert W
  • 1 Department of Neurology, University of Minnesota, MN, Minnesota.
Type
Published Article
Journal
Journal of vascular and interventional neurology
Publication Date
Jan 01, 2008
Volume
1
Issue
3
Pages
87–88
Identifiers
PMID: 20463862
Source
Medline
Language
English
License
Unknown

Abstract

BACKGROUND: We used data from the Minnesota Stroke Registry to examine rates of intravenous thrombolytic therapy in acute ischemic stroke and identifed opportunities to improve the utilization of this treatment. METHODS: We analyzed a total of 1010 acute ischemic stroke patients who had been entered into the registry by 13 participating hospitals during the first three quarters of the 2008 calendar year. RESULTS: Of the 1010 patients only 121 (12%) came within 2 hours of symptom onset. Intravenous recombinant tissue plasminogen activator (rt-PA) was administered to 32/55 (58%) of the patients who arrived within 2 hours of symptom onset and met eligibility criteria for this treatment. The remaining 66 patients had a documented reason for non-treatment. The most common reason (22/66) for non-treatment was rapid resolution of symptoms or mild stroke. Out of those 22 patients, 20 were ambulating independently prior to admission and only 9/20 (45%) ambulated independently at discharge. CONCLUSION: Further community education on the need for immediate medical attention after stroke is needed. Patients appropriately excluded from rt-PA treatment due to mild deficits or rapidly improving symptoms seem to have poor discharge outcomes. This subgroup of patients will have to be studied further, preferably in the context of a clinical trial.

Report this publication

Statistics

Seen <100 times